Treasurer of the State of North Carolina reduced its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,307 shares of the biotechnology company’s stock after selling 270 shares during the quarter. Treasurer of the State of North Carolina owned 0.06% of Sarepta Therapeutics worth $8,312,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in SRPT. Norges Bank bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at about $111,921,000. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 33.6% in the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after acquiring an additional 673,725 shares during the period. Prudential Financial Inc. raised its position in Sarepta Therapeutics by 1,473.5% in the first quarter. Prudential Financial Inc. now owns 396,074 shares of the biotechnology company’s stock worth $30,942,000 after acquiring an additional 370,902 shares during the period. Bellevue Group AG raised its position in Sarepta Therapeutics by 39.2% in the first quarter. Bellevue Group AG now owns 1,151,159 shares of the biotechnology company’s stock worth $89,929,000 after acquiring an additional 324,418 shares during the period. Finally, Mizuho Markets Cayman LP purchased a new position in shares of Sarepta Therapeutics in the first quarter worth about $35,809,000. 85.59% of the stock is owned by institutional investors.
Analyst Ratings Changes
SRPT has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their target price on shares of Sarepta Therapeutics from $217.00 to $213.00 in a research note on Friday, June 23rd. Morgan Stanley restated an “overweight” rating and issued a $183.00 price objective on shares of Sarepta Therapeutics in a report on Thursday. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $173.00 in a report on Monday, May 15th. Citigroup lowered their price objective on shares of Sarepta Therapeutics from $204.00 to $161.00 in a report on Friday, June 23rd. Finally, Cantor Fitzgerald lowered their price target on shares of Sarepta Therapeutics from $165.00 to $158.00 in a report on Wednesday, May 3rd. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.70.
Sarepta Therapeutics Stock Performance
SRPT opened at $107.35 on Friday. The company has a current ratio of 4.63, a quick ratio of 4.26 and a debt-to-equity ratio of 1.73. The company has a market cap of $10.00 billion, a price-to-earnings ratio of -8.46 and a beta of 0.98. The company’s 50 day moving average is $116.13 and its 200 day moving average is $126.16. Sarepta Therapeutics, Inc. has a 12-month low of $96.19 and a 12-month high of $159.89.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.62. Sarepta Therapeutics had a negative net margin of 114.30% and a negative return on equity of 128.64%. The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $255.99 million. During the same quarter in the previous year, the firm earned ($2.65) earnings per share. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts predict that Sarepta Therapeutics, Inc. will post -10.73 EPS for the current year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.
Receive News & Ratings for Sarepta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.